These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38924731)

  • 1. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age.
    Chehade M; Dellon ES; Spergel JM; Collins MH; Rothenberg ME; Pesek RD; Hirano I; Liu R; Laws E; Mortensen E; Martincova R; Shabbir A; McCann E; Kamal MA; Kosloski MP; Hamilton JD; Samuely C; Lim WK; Wipperman MF; Farrell A; Patel N; Yancopoulos GD; Glotfelty L; Maloney J
    N Engl J Med; 2024 Jun; 390(24):2239-2251. PubMed ID: 38924731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.
    Dellon ES; Rothenberg ME; Collins MH; Hirano I; Chehade M; Bredenoord AJ; Lucendo AJ; Spergel JM; Aceves S; Sun X; Kosloski MP; Kamal MA; Hamilton JD; Beazley B; McCann E; Patel K; Mannent LP; Laws E; Akinlade B; Amin N; Lim WK; Wipperman MF; Ruddy M; Patel N; Weinreich DR; Yancopoulos GD; Shumel B; Maloney J; Giannelou A; Shabbir A
    N Engl J Med; 2022 Dec; 387(25):2317-2330. PubMed ID: 36546624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Rothenberg ME; Dellon ES; Collins MH; Hirano I; Chehade M; Bredenoord AJ; Lucendo AJ; Spergel JM; Sun X; Hamilton JD; Mortensen E; Laws E; Maloney J; Mannent LP; McCann E; Liu X; Glotfelty L; Shabbir A
    Lancet Gastroenterol Hepatol; 2023 Nov; 8(11):990-1004. PubMed ID: 37660704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
    Hirano I; Dellon ES; Hamilton JD; Collins MH; Peterson K; Chehade M; Schoepfer AM; Safroneeva E; Rothenberg ME; Falk GW; Assouline-Dayan Y; Zhao Q; Chen Z; Swanson BN; Pirozzi G; Mannent L; Graham NMH; Akinlade B; Stahl N; Yancopoulos GD; Radin A
    Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
    Assa'ad AH; Gupta SK; Collins MH; Thomson M; Heath AT; Smith DA; Perschy TL; Jurgensen CH; Ortega HG; Aceves SS
    Gastroenterology; 2011 Nov; 141(5):1593-604. PubMed ID: 21835135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis.
    Rothenberg ME; Dellon ES; Collins MH; Bredenoord AJ; Hirano I; Peterson KA; Brooks L; Caldwell JM; Fjällbrant H; Grindebacke H; Ho CN; Keith M; McCrae C; Sinibaldi D; White WI; Datto CJ;
    N Engl J Med; 2024 Jun; 390(24):2252-2263. PubMed ID: 38924732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.
    Bacharier LB; Maspero JF; Katelaris CH; Fiocchi AG; Gagnon R; de Mir I; Jain N; Sher LD; Mao X; Liu D; Zhang Y; Khan AH; Kapoor U; Khokhar FA; Rowe PJ; Deniz Y; Ruddy M; Laws E; Patel N; Weinreich DM; Yancopoulos GD; Amin N; Mannent LP; Lederer DJ; Hardin M;
    N Engl J Med; 2021 Dec; 385(24):2230-2240. PubMed ID: 34879449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
    Hirano I; Collins MH; Assouline-Dayan Y; Evans L; Gupta S; Schoepfer AM; Straumann A; Safroneeva E; Grimm M; Smith H; Tompkins CA; Woo A; Peach R; Frohna P; Gujrathi S; Penenberg DN; Li C; Opiteck GJ; Olson A; Aranda R; Rothenberg ME; Dellon ES;
    Gastroenterology; 2019 Feb; 156(3):592-603.e10. PubMed ID: 30395812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
    Simpson EL; Bieber T; Guttman-Yassky E; Beck LA; Blauvelt A; Cork MJ; Silverberg JI; Deleuran M; Kataoka Y; Lacour JP; Kingo K; Worm M; Poulin Y; Wollenberg A; Soo Y; Graham NM; Pirozzi G; Akinlade B; Staudinger H; Mastey V; Eckert L; Gadkari A; Stahl N; Yancopoulos GD; Ardeleanu M;
    N Engl J Med; 2016 Dec; 375(24):2335-2348. PubMed ID: 27690741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.
    Bhatt SP; Rabe KF; Hanania NA; Vogelmeier CF; Bafadhel M; Christenson SA; Papi A; Singh D; Laws E; Patel N; Yancopoulos GD; Akinlade B; Maloney J; Lu X; Bauer D; Bansal A; Abdulai RM; Robinson LB;
    N Engl J Med; 2024 Jun; 390(24):2274-2283. PubMed ID: 38767614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.
    Spergel JM; Rothenberg ME; Collins MH; Furuta GT; Markowitz JE; Fuchs G; O'Gorman MA; Abonia JP; Young J; Henkel T; Wilkins HJ; Liacouras CA
    J Allergy Clin Immunol; 2012 Feb; 129(2):456-63, 463.e1-3. PubMed ID: 22206777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of dupilumab in the treatment of eosinophilic esophagitis.
    Syverson EP; Rubinstein E; Lee JJ; McDonald DR; Hait E
    Immunotherapy; 2024; 16(13):845-852. PubMed ID: 39073081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
    Bhatt SP; Rabe KF; Hanania NA; Vogelmeier CF; Cole J; Bafadhel M; Christenson SA; Papi A; Singh D; Laws E; Mannent LP; Patel N; Staudinger HW; Yancopoulos GD; Mortensen ER; Akinlade B; Maloney J; Lu X; Bauer D; Bansal A; Robinson LB; Abdulai RM;
    N Engl J Med; 2023 Jul; 389(3):205-214. PubMed ID: 37272521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical treatment of eosinophilic esophagitis.
    Franciosi JP; Gordon M; Sinopoulou V; Dellon ES; Gupta SK; Reed CC; Gutiérrez-Junquera C; Venkatesh RD; Erwin EA; Egiz A; Elleithy A; Mougey EB
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD004065. PubMed ID: 37470293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
    Castro M; Corren J; Pavord ID; Maspero J; Wenzel S; Rabe KF; Busse WW; Ford L; Sher L; FitzGerald JM; Katelaris C; Tohda Y; Zhang B; Staudinger H; Pirozzi G; Amin N; Ruddy M; Akinlade B; Khan A; Chao J; Martincova R; Graham NMH; Hamilton JD; Swanson BN; Stahl N; Yancopoulos GD; Teper A
    N Engl J Med; 2018 Jun; 378(26):2486-2496. PubMed ID: 29782217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial.
    Kliewer KL; Murray-Petzold C; Collins MH; Abonia JP; Bolton SM; DiTommaso LA; Martin LJ; Zhang X; Mukkada VA; Putnam PE; Kellner ES; Devonshire AL; Schwartz JT; Kunnathur VA; Rosenberg CE; Lyles JL; Shoda T; Klion AD; Rothenberg ME
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):803-815. PubMed ID: 37336228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
    Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
    N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
    Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.